Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.22 USD
Change Today -0.14 / -0.97%
Volume 41.0K
TBRA On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

tobira therapeutics inc (TBRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/7/14 - $27.09
52 Week Low
11/26/14 - $7.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tobira therapeutics inc (TBRA) Related Businessweek News

No Related Businessweek News Found

tobira therapeutics inc (TBRA) Details

Tobira Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis, and human immunodeficiency virus (HIV-1). Its cenicriviroc product is an immunomodulator and dual inhibitor of CCR2 and CCR5 that is being evaluated for the treatment of non-alcoholic steatohepatitis, HIV-1, and others. The company was founded in 2006 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 06/2/15
Founded in 2006

tobira therapeutics inc (TBRA) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.

tobira therapeutics inc (TBRA) Key Developments

Tobira Therapeutics, Inc. Appoints Ian Clements as Vice President, Investor Relations and Corporate Communications

Tobira Therapeutics, Inc. announced the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations and corporate communications. Dr. Clements brings over 20 years of industry experience to Tobira. Most recently he led investor relations and corporate communications at Avanir Pharmaceuticals, Inc. Previously he headed IR and corporate communications at Sequenom, Inc. Dr. Clements also held positions at the Trout Group and at Accelrys, Inc. Dr. Clements will join the company in July.

Tobira Therapeutics, Inc. Completes Patient Recruitment for CENTAUR Phase 2b Study of Cenicriviroc in NASH with Liver Fibrosis

Tobira Therapeutics, Inc. announced that it has completed recruitment for the Phase 2b CENTAUR study. CENTAUR is a global, double blind, placebo controlled, Phase 2b clinical trial evaluating the treatment effects of cenicriviroc (CVC) versus placebo in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis at high risk of progressive disease. NASH is a severe form of non-alcoholic fatty liver disease. Patients with NASH and risk factors such as liver fibrosis and type 2 diabetes or metabolic syndrome are often at higher risk for progression to more advanced liver complications such as cirrhosis and liver cancer. Results of the one-year primary endpoint are anticipated to be announced in mid-2016. Tobira plans to submit further detail regarding study demographics for presentation at an upcoming scientific conference. The primary endpoint of the CENTAUR study is a two-point improvement in NAS (NAFLD Activity Score) without progression of fibrosis. The study will evaluate additional surrogate endpoints, including resolution of NASH with no concurrent worsening of fibrosis stage and measures of fibrosis improvement. These endpoints have been the focus of subgroup analyses in other NASH studies as well as industry and regulatory agency dialog and Tobira anticipates they may form the basis for future regulatory approvals of therapies for NASH with liver fibrosis.

Tobira Therapeutics, Inc., Annual General Meeting, Jul 09, 2015

Tobira Therapeutics, Inc., Annual General Meeting, Jul 09, 2015., at 08:00 Pacific Standard Time. Location: the offices of the company, 701 Gateway Blvd, Suite 300. Agenda: To elect the three director nominees named in the proxy statement accompanying this notice to serve as Class II directors for a three-year term expiring at the annual meeting of stockholders in 2018 and until their successors are duly elected and qualified; to ratify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve amendments to and the material terms of 2013 Equity Compensation Plan, including an increase in the number of shares reserved for issuance thereunder by 1,200,000 and, among other amendments, increases in or imposition of certain share limits under such plan; and to transact such other business as may properly come before the annual meeting or any adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBRA:US $14.22 USD -0.14

TBRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TBRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation TBRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOBIRA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at